- Home
- MKZR vs PHGE Comparison
MKZR vs PHGE Comparison
Compare MKZR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- PHGE
- Stock Information
- Founded
- MKZR 2012
- PHGE 2015
- Country
- MKZR United States
- PHGE Israel
- Employees
- MKZR N/A
- PHGE N/A
- Industry
- MKZR
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- PHGE Health Care
- Exchange
- MKZR Nasdaq
- PHGE Nasdaq
- Market Cap
- MKZR 14.0M
- PHGE 14.6M
- IPO Year
- MKZR N/A
- PHGE N/A
- Fundamental
- Price
- MKZR $0.88
- PHGE $0.47
- Analyst Decision
- MKZR
- PHGE Strong Buy
- Analyst Count
- MKZR 0
- PHGE 1
- Target Price
- MKZR N/A
- PHGE $15.00
- AVG Volume (30 Days)
- MKZR 57.9K
- PHGE 122.3K
- Earning Date
- MKZR 05-15-2025
- PHGE 05-15-2025
- Dividend Yield
- MKZR 23.39%
- PHGE N/A
- EPS Growth
- MKZR N/A
- PHGE N/A
- EPS
- MKZR N/A
- PHGE N/A
- Revenue
- MKZR $23,037,348.00
- PHGE N/A
- Revenue This Year
- MKZR N/A
- PHGE N/A
- Revenue Next Year
- MKZR N/A
- PHGE N/A
- P/E Ratio
- MKZR N/A
- PHGE N/A
- Revenue Growth
- MKZR 52.64
- PHGE N/A
- 52 Week Low
- MKZR $0.79
- PHGE $0.44
- 52 Week High
- MKZR $5.50
- PHGE $4.13
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- PHGE 36.07
- Support Level
- MKZR N/A
- PHGE $0.47
- Resistance Level
- MKZR N/A
- PHGE $0.57
- Average True Range (ATR)
- MKZR 0.00
- PHGE 0.05
- MACD
- MKZR 0.00
- PHGE -0.00
- Stochastic Oscillator
- MKZR 0.00
- PHGE 20.41
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).